HomeCompareFNCDY vs ABBV

FNCDY vs ABBV: Dividend Comparison 2026

FNCDY yields 7.90% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FNCDY wins by $94930.07M in total portfolio value
10 years
FNCDY
FNCDY
● Live price
7.90%
Share price
$15.77
Annual div
$1.25
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94930.18M
Annual income
$92,676,928,380.73
Full FNCDY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FNCDY vs ABBV

📍 FNCDY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFNCDYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FNCDY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FNCDY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FNCDY
Annual income on $10K today (after 15% tax)
$671.61/yr
After 10yr DRIP, annual income (after tax)
$78,775,389,123.62/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FNCDY beats the other by $78,775,368,067.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FNCDY + ABBV for your $10,000?

FNCDY: 50%ABBV: 50%
100% ABBV50/50100% FNCDY
Portfolio after 10yr
$47465.14M
Annual income
$46,338,476,576.25/yr
Blended yield
97.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FNCDY
No analyst data
Altman Z
0.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FNCDY buys
0
ABBV buys
0
No recent congressional trades found for FNCDY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFNCDYABBV
Forward yield7.90%3.06%
Annual dividend / share$1.25$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$94930.18M$102.3K
Annual income after 10y$92,676,928,380.73$24,771.77
Total dividends collected$94776.25M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FNCDY vs ABBV ($10,000, DRIP)

YearFNCDY PortfolioFNCDY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,280$1,580.27$11,550$430.00+$730.00FNCDY
2$16,767$3,627.31$13,472$627.96+$3.3KFNCDY
3$27,198$9,257.27$15,906$926.08+$11.3KFNCDY
4$57,170$28,067.81$19,071$1,382.55+$38.1KFNCDY
5$171,448$110,276.31$23,302$2,095.81+$148.1KFNCDY
6$801,600$618,150.10$29,150$3,237.93+$772.5KFNCDY
7$6,259,842$5,402,130.14$37,536$5,121.41+$6.22MFNCDY
8$85,550,838$78,852,806.99$50,079$8,338.38+$85.50MFNCDY
9$2,105,840,060$2,014,300,663.78$69,753$14,065.80+$2105.77MFNCDY
10$94,930,177,245$92,676,928,380.73$102,337$24,771.77+$94930.07MFNCDY

FNCDY vs ABBV: Complete Analysis 2026

FNCDYStock

A preferred real estate player at the European level, Covivio is close to its end users, capturing their aspirations, combining work, travel, living, and co-inventing vibrant spaces. A benchmark in the European real estate market with €25 Billion in assets, Covivio offers support to companies, hotel brands and territories in their pursuit for attractiveness, transformation and responsible performance.

Full FNCDY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FNCDY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FNCDY vs SCHDFNCDY vs JEPIFNCDY vs OFNCDY vs KOFNCDY vs MAINFNCDY vs JNJFNCDY vs MRKFNCDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.